Can targeting Rho GTPases be a therapeutic strategy in Cancer?
Yes, targeting Rho GTPases holds therapeutic potential in cancer. Inhibitors of Rho GTPases and their regulators are being explored to hinder cancer cell proliferation, invasion, and metastasis. For example, fasudil, a Rho kinase inhibitor, has shown promise in preclinical studies. However, the specificity and systemic toxicity of such inhibitors remain a challenge.
